VA Greater Los Angeles Healthcare System | West Los Angeles VA Medical Center - Cardiology Department

Research site

(Unclaimed)

Location

11301 Wilshire Boulevard, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Enzalutamide

Docetaxel

Selonsertib

Rucaparib

Copper Cu 64

Darusentan

Ralinepag

Apixaban

Acetylcysteine

Olpasiran

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 72 total trials

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) st...

Enrolling

Hypertension

Familial Primary Pulmonary Hypertension

Drug: Ralinepag

Drug: Placebo

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only

Hypertension

Familial Primary Pulmonary Hypertension

Drug: Ralinepag

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting

Metastatic Castration Resistant Prostate Cancer

Drug: Abiraterone acetate or Enzalutamide or Docetaxel

Drug: Rucaparib

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfa...

Enrolling

Prostate Adenocarcinoma

Prostate Cancer

Drug: Copper Cu 64 PSMA I&T

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate c...

Enrolling

Biochemical Recurrence of Malignant Neoplasm of Prostate

Prostate Adenocarcinoma

Drug: Copper Cu 64 PSMA I&T

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when use...

Active, not recruiting

Pulmonary Arterial Hypertension

Device: Model 10642 Implantable Intravascular Catheter

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting

Stroke

Myocardial Infarction

Drug: Evolocumab

Drug: Routine Lipid Management

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safe...

Enrolling

Metastatic Castration-resistant Prostate Cancer

Drug: FPI-2265

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Olpasiran

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent)

The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-met...

Active, not recruiting

Adenocarcinoma of the Prostate

Biological: sipuleucel-T

PSMA PET Scan and mpMRI for Prostate Cancer Detection

Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate can...

Not yet enrolling

Prostate Cancer Diagnosis

Drug: 18F- DCFPyl Injection

Diagnostic Test: PSMA PET scan

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

The purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate canc...

Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer

Drug: Enzalutamide

Drug: Abiraterone

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in comb...

Active, not recruiting

Metastatic Prostate Cancer

Castration-resistant Prostate Cancer

Drug: I-131-1095

Drug: Enzalutamide

Study of INKmune in Patients With mCRPC (CaRe Prostate)

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenousl...

Enrolling

mCRPC

Metastatic Castration-resistant Prostate Cancer

Biological: INKmune

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling

Cancer

Drug: Darolutamide (Nubeqa, BAY1841788)